BRIEF — Roche Receives FDA's Approval For Its Enspryng, A First — In — Class IL — 6R Inhibitor
Oct 16 (Reuters) — ROCHE HOLDING AG: Fda Approves Roche’s Enspryng, A First-in-class Il-6r Inhibitor, As The First And Only At-home Subcutaneous Treatment Option For Thyroid Eye Disease (Ted) Roche Holding Ag - Enspryng Offers First At-home Subcutaneous Treatment Option For Ted Roche Holding Ag - Fda Approval Based On